Clarus Therapeutics Holdings Inc. [NASDAQ: CRXT] closed the trading session at $1.79 on 01/06/22. The day’s price range saw the stock hit a low of $1.70, while the highest price level was $2.15. The company report on December 7, 2021 that Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement.
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has closed its previously announced definitive agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to Clarus from the private placement, before deducting the placement agents’ fees and other estimated offering expenses payable by Clarus, resulted in approximately $15 million.
The stocks have a year to date performance of -26.34 percent and weekly performance of -28.40 percent. The stock has been moved at -82.24 percent over the last six months. The stock has performed -62.08 percent around the most recent 30 days and changed -50.96 percent over the most recent 3-months.
If compared to the average trading volume of 2.18M shares, CRXT reached to a volume of 3560829 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Clarus Therapeutics Holdings Inc. [CRXT]:
The Average True Range (ATR) for Clarus Therapeutics Holdings Inc. is set at 0.44, with the Price to Sales ratio for CRXT stock in the period of the last 12 months amounting to 3.39.
CRXT stock trade performance evaluation
Clarus Therapeutics Holdings Inc. [CRXT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.40. With this latest performance, CRXT shares dropped by -62.08% in over the last four-week period, additionally sinking by -82.24% over the last 6 months .
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRXT stock in for the last two-week period is set at 24.18, with the RSI for the last a single of trading hit 15.77, and the three-weeks RSI is set at 29.67 for Clarus Therapeutics Holdings Inc. [CRXT]. The present Moving Average for the last 50 days of trading for this stock 4.1413, while it was recorded at 2.1600 for the last single week of trading, and 7.7494 for the last 200 days.
Clarus Therapeutics Holdings Inc. [CRXT]: An insightful look at the core fundamentals
Clarus Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.70.
Clarus Therapeutics Holdings Inc. [CRXT]: Insider Ownership positions
There are presently around $5 million, or 82.70% of CRXT stock, in the hands of institutional investors. The top three institutional holders of CRXT stocks are: BRACEBRIDGE CAPITAL, LLC with ownership of 2,002,495, which is approximately New of the company’s market cap and around 43.20% of the total institutional ownership; TELEMETRY INVESTMENTS, L.L.C., holding 45,000 shares of the stock with an approximate value of $90000.0 in CRXT stocks shares; and TOWER RESEARCH CAPITAL LLC (TRC), currently with $87000.0 in CRXT stock with ownership of nearly New of the company’s market capitalization.
Positions in Clarus Therapeutics Holdings Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 11 institutional holders increased their position in Clarus Therapeutics Holdings Inc. [NASDAQ:CRXT] by around 2,257,578 shares. Additionally, 31 investors decreased positions by around 5,061,644 shares, while 0 investors held positions by with 5,058,335 shares. The mentioned changes placed institutional holdings at 2,260,887 shares, according to the latest SEC report filing. CRXT stock had 9 new institutional investments in for a total of 2,221,933 shares, while 30 institutional investors sold positions of 4,903,619 shares during the same period.